Skip to Main content Skip to Navigation
Journal articles

Changes in Gut Microbiota by Chronic Stress Impair the Efficacy of Fluoxetine

Abstract : Major depressive disorders (MDDs) constitute a leading cause of disability worldwide and current pharmacological treatments are partially effective. The gut microbiota (GM) has recently emerged as a target of therapeutic interest for MDDs. In this study, we transfer GM from mice that sustained unpredictable chronic mild stress (UCMS) to healthy recipient mice. The fecal transfer induces despair-like behavior, decreases neurogenesis in the hippocampus (HpC), and impairs the antidepressant and neurogenic effects of a standard selective serotonin (5-HT) reuptake inhibitor, fluoxetine (FLX). These effects are paralleled by deficits in 5-HT bioavailability, biosynthesis, and reuptake in the HpC. Treatment with 5-hydroxytryptophan restores the levels of 5-HT and its precursors in the HpC, improves HpC neurogenesis, and alleviates despair-like symptoms. Our results reveal that stress-induced changes in GM are involved in the pathogenesis of depressive disorders and minimize FLX efficacy via alterations in the serotonergic pathway of Trp metabolism.
Document type :
Journal articles
Complete list of metadata
Contributor : Bérengère HUGOT Connect in order to contact the contributor
Submitted on : Friday, June 11, 2021 - 11:30:06 AM
Last modification on : Thursday, April 7, 2022 - 10:10:39 AM


Publication funded by an institution


Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License




Eleni Siopi, Grégoire Chevalier, Lida Katsimpardi, Soham Saha, Mathilde Bigot, et al.. Changes in Gut Microbiota by Chronic Stress Impair the Efficacy of Fluoxetine. Cell Reports, Elsevier Inc, 2020, 30 (11), pp.3682 - 3690.e6. ⟨10.1016/j.celrep.2020.02.099⟩. ⟨pasteur-03257987⟩



Record views


Files downloads